SyntekaBio Statistics
Total Valuation
SyntekaBio has a market cap or net worth of KRW 57.37 billion. The enterprise value is 48.15 billion.
| Market Cap | 57.37B |
| Enterprise Value | 48.15B |
Important Dates
The last earnings date was Friday, April 3, 2026.
| Earnings Date | Apr 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SyntekaBio has 24.26 million shares outstanding. The number of shares has increased by 2.16% in one year.
| Current Share Class | 24.26M |
| Shares Outstanding | 24.26M |
| Shares Change (YoY) | +2.16% |
| Shares Change (QoQ) | +8.40% |
| Owned by Insiders (%) | 15.69% |
| Owned by Institutions (%) | n/a |
| Float | 20.45M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.73 |
| PB Ratio | 1.81 |
| P/TBV Ratio | 1.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.77 |
| EV / Sales | 14.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.52 |
Financial Position
The company has a current ratio of 1.42, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.42 |
| Quick Ratio | 1.41 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.67 |
| Interest Coverage | -3.79 |
Financial Efficiency
Return on equity (ROE) is -61.27% and return on invested capital (ROIC) is -18.91%.
| Return on Equity (ROE) | -61.27% |
| Return on Assets (ROA) | -14.91% |
| Return on Invested Capital (ROIC) | -18.91% |
| Return on Capital Employed (ROCE) | -31.39% |
| Weighted Average Cost of Capital (WACC) | 9.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -69.29% in the last 52 weeks. The beta is 0.52, so SyntekaBio's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | -69.29% |
| 50-Day Moving Average | 3,035.70 |
| 200-Day Moving Average | 4,072.05 |
| Relative Strength Index (RSI) | 33.43 |
| Average Volume (20 Days) | 237,116 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SyntekaBio had revenue of KRW 3.43 billion and -17.38 billion in losses. Loss per share was -1,115.48.
| Revenue | 3.43B |
| Gross Profit | 3.42B |
| Operating Income | -10.76B |
| Pretax Income | -17.38B |
| Net Income | -17.38B |
| EBITDA | -8.74B |
| EBIT | -10.76B |
| Loss Per Share | -1,115.48 |
Balance Sheet
The company has 16.35 billion in cash and 7.13 billion in debt, with a net cash position of 9.22 billion or 380.04 per share.
| Cash & Cash Equivalents | 16.35B |
| Total Debt | 7.13B |
| Net Cash | 9.22B |
| Net Cash Per Share | 380.04 |
| Equity (Book Value) | 31.78B |
| Book Value Per Share | 1,310.02 |
| Working Capital | 5.19B |
Cash Flow
In the last 12 months, operating cash flow was -10.65 billion and capital expenditures -11.01 million, giving a free cash flow of -10.66 billion.
| Operating Cash Flow | -10.65B |
| Capital Expenditures | -11.01M |
| Depreciation & Amortization | 2.02B |
| Net Borrowing | -8.85B |
| Free Cash Flow | -10.66B |
| FCF Per Share | -439.47 |
Margins
| Gross Margin | 99.87% |
| Operating Margin | -313.91% |
| Pretax Margin | -506.76% |
| Profit Margin | n/a |
| EBITDA Margin | -254.90% |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SyntekaBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.16% |
| Shareholder Yield | -2.16% |
| Earnings Yield | -30.29% |
| FCF Yield | -18.58% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SyntekaBio has an Altman Z-Score of 0.46 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.46 |
| Piotroski F-Score | 4 |